公开(公告)号：US20110166067A1

公开(公告)日：2011-07-07

申请号：US13003760

申请日：2008-12-11

申请人： Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Nicholas Goldspink ,  Kerry Nield ,  Abdul Sattar ,  James Bush

发明人： Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Nicholas Goldspink ,  Kerry Nield ,  Abdul Sattar ,  James Bush

IPC分类号： A61K38/18 ,  C07K14/495 ,  A61P17/02 ,  A61P9/00

CPC分类号： A61K38/1841

摘要： The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-β3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment TGF-β3 is provided to each centimetre of wound margin in a larger therapeutically effective amount of TGF-β3. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.

摘要翻译： 本发明提供使用TGF-β3抑制人类瘢痕形成的新治疗方法，以及用于抑制人瘢痕形成的新用途的TGF-β3。 在治疗的第一次发生中，TGF-β1被提供给每个厘米的伤口边缘或每厘米的伤口以第一治疗有效量形成的部位; 并且在随后的治疗发生中，在更大的治疗有效量的TGF-βb中，向伤口边缘的每厘米提供TGF-β; 3。 治疗的发生发生在彼此之间8小时至48小时之间。 TGF-β可以通过皮内注射来提供。 还提供了选择用于抑制与人类伤口愈合相关的瘢痕形成的适当治疗方案的试剂盒和方法。

公开(公告)号：US20100144690A1

公开(公告)日：2010-06-10

申请号：US12520496

申请日：2007-12-23

申请人： Mark W. J. Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

发明人： Mark W. J. Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

IPC分类号： A61K31/57 ,  A61K31/575 ,  A61P17/02

CPC分类号： A61K31/57 ,  A61K31/575 ,  A61K31/58

摘要： Provided are antagonists of FXR activity for use as medicament for the prevention, reduction or inhibition of scarring. This use may preferably be to prevent, reduce or inhibit scarring formed on healing of wounds. The invention also provides corresponding methods of treatment. Preferred antagonists of FXR activity include guggulsterone (Z); guggulsterone (E); a scalarane; 80-574; and a 5α-bile alcohol. In advantageous embodiments, up to 32 μM of the antagonist of FXR activity may be provided per linear cm of wound, or cm2 of a wound or fibrotic disorder, over a 24 hour period in order to inhibit scarring.

摘要翻译： 提供FXR活性的拮抗剂，用作预防，减少或抑制瘢痕形成的药物。 该用途可以优选地是防止，减少或抑制伤口愈合时形成的瘢痕形成。 本发明还提供相应的治疗方法。 优选的FXR活性拮抗剂包括苦瓜酮（Z）; 格鲁斯酮（E）; 一个标准 80-574; 和5α-胆汁醇。 在有利的实施方案中，为了抑制瘢痕形成，可以在24小时内每线性cm伤口或cm2的伤口或纤维化病症提供高达32μM的FXR活性拮抗剂。

公开(公告)号：US20100204248A1

公开(公告)日：2010-08-12

申请号：US12671005

申请日：2008-07-31

申请人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

发明人： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

IPC分类号： A61K31/52 ,  C07D473/38 ,  A61P17/02

CPC分类号： A61K31/407 ,  A61K31/52

摘要： Provided is the use of an agonist of a member of the nuclear hormone receptor NR4A subgroup in the manufacture of a medicament for the prevention, reduction or inhibition of scarring in a non-ocular tissue. Also provided is a method of preventing, reducing or inhibiting scarring in a non-ocular tissue, the method comprising administering a therapeutically effective amount of an agonist of a member of the nuclear hormone receptor NR4A subgroup to a patient in need of such prevention, reduction or inhibition. The NR4A agonist may be 6-mercaptopurine. The medicaments and methods may preferably be used to prevent, reduce or inhibit scarring in the skin. The medicaments and methods of the invention may be used to accelerate healing of wounds.

摘要翻译： 提供了核激素受体NR4A亚组的成员的激动剂在制备用于预防，减少或抑制非眼组织中的瘢痕形成的药物中的用途。 还提供了一种在非眼组织中预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，还原的患者施用治疗有效量的激素受体NR4A亚组成员的激动剂 或抑制。 NR4A激动剂可以是6-巯基嘌呤。 药物和方法可优选用于预防，减少或抑制皮肤中的瘢痕形成。 本发明的药物和方法可用于加速伤口愈合。

公开(公告)号：US20100137201A1

公开(公告)日：2010-06-03

申请号：US12306501

申请日：2007-06-29

申请人： Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

发明人： Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

IPC分类号： A61K38/17 ,  C07K14/435

CPC分类号： A61K38/1709

摘要： There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided.

摘要翻译： 提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防，减少或抑制瘢痕形成的药物中的用途。 还提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防和/或治疗纤维化病症的药物中的用途。 另外的方面涉及可以预防，减少或抑制瘢痕形成的方法，以及可以通过哪些可以预防和/或治疗纤维化疾病。 还提供了可用于本发明的药物或方法中的治疗有效量的WNT5A或其片段或衍生物。